As more and more cases of titinopathy are recognized and reported, the gestalt of TTN mutation-compatible phenotypes across age groups is starting to emerge. In addition to the clinical phenotype on examination, the deeper phenotype also includes TTN-compatible muscle imaging patterns, such as involvement of the tibialis anterior and of the semitendinosus muscle in the thigh, 13 and the muscle histological appearances that are
compatible with TTN mutations (the histotype). The increasing knowledge about the functional consequences of the recognized mutations (the physiotype), including Western blot analysis (as convincingly laid out in Savarese et al 2 ), together with modeling mutations in animal and in silico models will add a powerful layer to the diagnostic approach. While none or few phenotypic, histological, or functional features in isolation may be entirely diagnostic or specific for a TTN-related disorder, their interplay with the genotype creates a good number of combinations that would be TTN compatible as well as those that would be TTN incompatible, thus helping to assign plausibility to a still tentative interpretation of the genotype. A typical example would be a patient with a convincing truncating TTN mutation and a missense TTN variant of unknown significance in compound heterozygosity, ie, inherited from either parent. If the patient has a phenotype and muscle imaging pattern that is recognizable as falling within the spectrum of emerging recessive titinopathy and additionally has a consistent TTN histotype (for instance, frequent nuclear centralization and some corelike areas), it would be justified to now assign the missense mutation putative causality. However, if only 1 convincing TTN mutation has been found in a patient with the same compatible phenotype and histotype , one would then strongly suspect that there might be a second, as-of-yet hidden mutation in TTN on the other allele that needs to be addressed with different technology (such as whole-genome sequencing and RNA sequencing).
14 Ideally, this accumulating collective genotypic, functional, and phenotypic knowledge needs to be captured in a central and accessible database platform with the goal of an ever-improving prediction algorithm for determining the effect (physiotype) of any given TTN variant and its associated phenotypes. 15 At some point, it may then be possible to confidently diagnose patients with 2 TTN missense alleles, as patients with this genetic scenario must undoubtedly exist. Clearly, the time to take initiative and accept TTN's titanic challenge is now. (Table) . Because of this increase in submissions as well as our rise in impact factor to more than 10, we have needed to become more selective and had an overall acceptance rate of 12% and an acceptance rate of 9% for research articles. Despite this higher volume, the journal's editors and reviewers have put in numerous hours to ensure we continue to have a rapid response time, with a median time from receipt to first decision of 1 day without peer review and 8 days with peer review.
ARTICLE INFORMATION
Impact factor is only one measure of a journal's success, and we have emphasized online offerings and social media outlets as important ways to reach our readers and to magnify the effect of the articles we publish. In 2017, there were a record 4.1 million downloads of content via our redesigned website (http://www .jamaneurology.com). The journal has nearly 39 000 Facebook followers and 22 000 Twitter followers. In 2017, JAMA Neurology had 14 of the top 50 articles in major neurology journals with Altmetric scores, a measure of articles' news and social media coverage, including the 3 articles listed in the Table. 2-4 Although we continue to hear from readers about the importance of a monthly print issue publication, the journal has increasingly transformed into a weekly online journal in which new content is rapidly published each Monday morning and sent to more than 38 000 recipients of our electronic table of contents.
We have continued to publish outstanding research across an increasingly broad set of neurologic subspecialties and topics. One of our most important initiatives in the past year has been working to make the journal's articles more diverse than ever, striving to cover all aspects of neurology. Increasing emphasis on clinical trials as well as publishing the best translational research has allowed us to focus on articles that help in clinical practice while framing the future of neurology and neuroscience.
In addition, as a new editorial team wrapping up our first year, we have worked extremely hard to connect with readers and to take suggestions about how to improve our content. In addition to the popular Viewpoints section, we have added additional opportunities to address humanistic areas of neurology with our On the Brain series while continuing to boost our educational content with Clinical Challenges as well as more Continuing Medical Education offerings and podcasts.
At the end of the day, JAMA Neurology is your journal, not ours, and we would very much appreciate any suggestions you have to help us better serve your needs. Thanks to all who have been part of the team, and we can't wait to see what 2018 will bring.
